awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33730396-18C3B5E6-F2F2-4549-8F35-B78B1696D1C7
Q33730396-18C3B5E6-F2F2-4549-8F35-B78B1696D1C7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33730396-18C3B5E6-F2F2-4549-8F35-B78B1696D1C7
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
P2860
Q33730396-18C3B5E6-F2F2-4549-8F35-B78B1696D1C7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33730396-18C3B5E6-F2F2-4549-8F35-B78B1696D1C7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fd2eb899551b0a37c3334835c1919be9746d9bc7
P2860
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.